Dr Elaine Dunlop
Research Associate
- dunlopea@cardiff.ac.uk
- +44 (0)29 2068 7785
- Adeilad Geneteg Canser, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
- Ar gael fel goruchwyliwr ôl-raddedig
Trosolwg
'Working towards tailored therapies for inherited diseases and cancer'
My research centres on the inherited conditions, Tuberous Sclerosis Complex (TSC) and Birt-Hogg-Dubé (BHD) syndrome where patients are predisposed to develop cysts and tumours. I aim to understand what is malfunctioning in these cells at a molecular level, with the goal of identifying weaknesses which could be specifically targeted by therapies. As there is crossover between the altered growth pathways observed in these genetic diseases and the pathways which are at fault in sporadic cancer, these future treatments could also be effective for the wider cancer community. Therefore, through a better understanding of disease processes we can work towards stratifying patients based on the genetics of their disease and treating them with appropriately tailored therapies.
Cyhoeddiadau
2019
- Ni Bhaoighill, M. and Dunlop, E. A. 2019. Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics. Cancer Drug Resistance 2019(2), pp. 1069-1085. (10.20517/cdr.2019.87)
2018
- Johnson, C. E. et al. 2018. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir−bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. Oncogene 37, pp. 5913-5925. (10.1038/s41388-018-0381-2)
- McCann, H., Johnson, C., Errington, R., Davies, D. M., Dunlop, E. and Tee, A. 2018. Energy stress-mediated cytotoxicity in tuberous sclerosis complex 2-deficient cells with nelfinavir and mefloquine treatment. Cancers 10(10), pp. -., article number: 375. (10.3390/cancers10100375)
- Yeung, V. et al. 2018. Rab35-dependent extracellular nanovesicles are required for induction of tumour supporting stroma. Nanoscale 10(18), pp. 8547-8559. (10.1039/C8NR02417K)
2017
- Carroll, B. and Dunlop, E. A. 2017. The lysosome: a crucial hub for AMPK and mTORC1 signalling. Biochemical Journal 474(9), pp. 1453-1466. (10.1042/BCJ20160780)
- Dunlop, E. A., Johnson, C., Wiltshire, M., Errington, R. J. and Tee, A. 2017. Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively. Oncotarget (10.18632/oncotarget.16232)
2016
- Dodd, K. M. and Dunlop, E. A. 2016. Tuberous sclerosis—A model for tumour growth. Seminars in Cell and Developmental Biology 52, pp. 3-11. (10.1016/j.semcdb.2016.01.025)
- Carroll, B. et al. 2016. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. eLife 5, pp. -., article number: e11058. (10.7554/eLife.11058)
2014
- Dunlop, E. and Tee, A. 2014. mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Seminars in Cell and Developmental Biology 36, pp. 121-129. (10.1016/j.semcdb.2014.08.006)
- Yan, M. et al. 2014. The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. Journal of Clinical Investigation 124(6), pp. 2640-2650. (10.1172/JCI71749)
- Dunlop, E. et al. 2014. FLCN, a novel autophagy component, interacts with GABARAP and is regulated by ULK1 phosphorylation. Autophagy 10(10), pp. 1749-1760. (10.4161/auto.29640)
2013
- Zhang, J. et al. 2013. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. Nature Cell Biology 15(10), pp. 1186-1195. (10.1038/ncb2822)
2012
- Thomas, L., Richards, M., Mort, M. E., Dunlop, E. A., Cooper, D. N. and Upadhyaya, M. 2012. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene. Human Mutation 33(12), pp. 1687-1696. (10.1002/humu.22162)
2011
- Dunlop, E. A., Hunt, D. K., Acosta-Jaquez, H. A., Fingar, D. C. and Tee, A. 2011. ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. Autophagy 7(7), pp. 737-747. (10.4161/auto.7.7.15491)
- Dunlop, E. A. et al. 2011. Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence. European Journal of Human Genetics 19(7), pp. 789-795. (10.1038/ejhg.2011.38)
- Preston, R. S. et al. 2011. Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene 30(10), pp. 1159-1173. (10.1038/onc.2010.497)
2010
- Soliman, G. A., Acosta-Jaquez, H. A., Dunlop, E. A., Ekim, B., Maj, N. E., Tee, A. and Fingar, D. C. 2010. mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific Catalytic Activity and Clarifies Rapamycin Mechanism of Action. Journal of Biological Chemistry 285(11), pp. 7866-7879. (10.1074/jbc.M109.096222)
- Shi, Z., Hodges, V. M., Dunlop, E. A., Percy, M. J., Maxwell, A. P., El-Tanani, M. and Lappin, T. R. J. 2010. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Molecular Cancer Research 8(4), pp. 615-626. (10.1158/1541-7786.MCR-09-0264)
2009
- Dunlop, E. A., Dodd, K. M., Seymour, L. A. and Tee, A. 2009. Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition. Cellular Signalling 21(7), pp. 1073-1084. (10.1016/j.cellsig.2009.02.024)
- Dunlop, E. A. and Tee, A. 2009. Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms. Cellular Signalling 21(6), pp. 827-835. (10.1016/j.cellsig.2009.01.012)
2007
- Dunlop, E. A., Maxwell, A. P. and Lappin, T. R. J. 2007. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells 25(2), pp. 380-384. (10.1634/stemcells.2006-0452)
2006
- Brown, W. M. et al. 2006. Erythropoietin receptor expression in non-Small cell lung carcinoma: a question of antibody specificity. Stem Cells 25(3), pp. 718-722. (10.1634/stemcells.2006-0687)
- Dunlop, E. A., Percy, M. J., Boland, M. P., Maxwell, A. P. and Lappin, T. R. 2006. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegenerative Diseases 3(1-2), pp. 94-100. (10.1159/000092099)